Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · November 17, 2022

Bivalirudin Plus a High-Dose Infusion vs Heparin Monotherapy in Patients With STEMI Undergoing Primary PCI

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
Lancet 2022 Nov 04;[EPub Ahead of Print], Y Li, Z Liang, L Qin, M Wang, X Wang, H Zhang, Y Liu, Y Li, Z Jia, L Liu, H Zhang, J Luo, S Dong, J Guo, H Zhu, S Li, H Zheng, L Liu, Y Wu, Y Zhong, M Qiu, Y Han, GW Stone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading